Exact Mass: 337.0403058

Exact Mass Matches: 337.0403058

Found 35 metabolites which its exact mass value is equals to given mass value 337.0403058, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

   

famotidine

Famotidine (Pepcid)

C8H15N7O2S3 (337.044933)


A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BA - H2-receptor antagonists C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

   

Famotidine

3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide

C8H15N7O2S3 (337.044933)


Famotidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). It is commonly marketed by Merck under the trade names Pepcidine and Pepcid. [HMDB] Famotidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). It is commonly marketed by Merck under the trade names Pepcidine and Pepcid. A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BA - H2-receptor antagonists D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

   

1H-Imidazole-1-ethanol, 2-nitro-alpha-((2,2,2-trifluoro-1-(trifluoromethyl)ethoxy)methyl)-

1H-Imidazole-1-ethanol, 2-nitro-alpha-((2,2,2-trifluoro-1-(trifluoromethyl)ethoxy)methyl)-

C9H9F6N3O4 (337.04972260000005)


   
   

Pepcid

famotidine

C8H15N7O2S3 (337.044933)


CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2002; ORIGINAL_PRECURSOR_SCAN_NO 2000 A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BA - H2-receptor antagonists C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1942; ORIGINAL_PRECURSOR_SCAN_NO 1939 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1950; ORIGINAL_PRECURSOR_SCAN_NO 1949 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1959; ORIGINAL_PRECURSOR_SCAN_NO 1957 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1977; ORIGINAL_PRECURSOR_SCAN_NO 1975 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2003; ORIGINAL_PRECURSOR_SCAN_NO 2000 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4186; ORIGINAL_PRECURSOR_SCAN_NO 4184 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4210; ORIGINAL_PRECURSOR_SCAN_NO 4209 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4236; ORIGINAL_PRECURSOR_SCAN_NO 4235 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4229; ORIGINAL_PRECURSOR_SCAN_NO 4227 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4226; ORIGINAL_PRECURSOR_SCAN_NO 4225 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4191; ORIGINAL_PRECURSOR_SCAN_NO 4189 Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

   

4-(Bromomethyl)-N,N-diphenylaniline

4-(Bromomethyl)-N,N-diphenylaniline

C19H16BrN (337.0466036)


   

1-[(3,4-dichlorophenyl)methylamino]cyclohexane-1-carboxylic acid

1-[(3,4-dichlorophenyl)methylamino]cyclohexane-1-carboxylic acid

C14H18Cl3NO2 (337.0403058)


   

Methyl 1-(5-bromopyridin-2-yl)-5-(tert-butyl)-1H-pyrazole-4-carboxylate

Methyl 1-(5-bromopyridin-2-yl)-5-(tert-butyl)-1H-pyrazole-4-carboxylate

C14H16BrN3O2 (337.0425816)


   

1-[(2,4-dichlorophenyl)methylamino]cyclohexane-1-carboxylic acid

1-[(2,4-dichlorophenyl)methylamino]cyclohexane-1-carboxylic acid

C14H18Cl3NO2 (337.0403058)


   

Benzyl 2,4-dichloro-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate

Benzyl 2,4-dichloro-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate

C15H13Cl2N3O2 (337.0384778)


   

1-(4-CHLORO-3-NITROPHENYL)-2-PHENYLETHANONE

1-(4-CHLORO-3-NITROPHENYL)-2-PHENYLETHANONE

C17H11ClF3NO (337.0481222)


   

2-BENZOTHIAZOLYL-3-(4-CARBOXY-2-METHOXYPHENYL)-5-[4-(2-SULFOETHYLCARBAMOYL)PHENYL]-2H-TETRAZOLIUM

2-BENZOTHIAZOLYL-3-(4-CARBOXY-2-METHOXYPHENYL)-5-[4-(2-SULFOETHYLCARBAMOYL)PHENYL]-2H-TETRAZOLIUM

C10H16N3O6PS (337.0497406)


   

4-nitrophenyl-beta-d-glucuronic acid, sodium salt

4-nitrophenyl-beta-d-glucuronic acid, sodium salt

C12H12NNaO9 (337.0409742)


   
   

Benzyl 2,4-dichloro-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate

Benzyl 2,4-dichloro-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate

C15H13Cl2N3O2 (337.0384778)


   

1-[(3-Bromo-1H-pyrrolo[2,3-b]pyridin-2-yl)methyl]-4-piperidinecar boxylic acid

1-[(3-Bromo-1H-pyrrolo[2,3-b]pyridin-2-yl)methyl]-4-piperidinecar boxylic acid

C14H16BrN3O2 (337.0425816)


   

N-( 4-Bromophenyl)-N-(4-methylphenyl)aniline

N-( 4-Bromophenyl)-N-(4-methylphenyl)aniline

C19H16BrN (337.0466036)


   

Ethyl 3-[(E)-2-Amino-1-Cyanoethenyl]-6,7-Dichloro-1-Methyl-1h-Indole-2-Carboxylate

Ethyl 3-[(E)-2-Amino-1-Cyanoethenyl]-6,7-Dichloro-1-Methyl-1h-Indole-2-Carboxylate

C15H13Cl2N3O2 (337.0384778)


   

3-[(5Z)-5-[(4-ethoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid

3-[(5Z)-5-[(4-ethoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid

C15H15NO4S2 (337.044247)


   

3-[(2-Chloro-6-fluorophenyl)methylthio]-4-ethyl-5-(2-furanyl)-1,2,4-triazole

3-[(2-Chloro-6-fluorophenyl)methylthio]-4-ethyl-5-(2-furanyl)-1,2,4-triazole

C15H13ClFN3OS (337.04518500000006)


   

[(2R,3S,4R,5R)-5-(4-carbamoyl-5-oxidoimidazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate

[(2R,3S,4R,5R)-5-(4-carbamoyl-5-oxidoimidazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate

C9H12N3O9P-2 (337.0311152)


   
   

5-Hydroxycytidine monophosphate

5-Hydroxycytidine monophosphate

C9H12N3O9P-2 (337.0311152)


   

4-carbamoyl-1-(5-O-phosphonato-beta-D-ribofuranosyl)-1H-imidazol-3-ium-5-olate

4-carbamoyl-1-(5-O-phosphonato-beta-D-ribofuranosyl)-1H-imidazol-3-ium-5-olate

C9H12N3O9P-2 (337.0311152)


D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D000970 - Antineoplastic Agents D018501 - Antirheumatic Agents D004791 - Enzyme Inhibitors

   

2,4,7,9-Tetrahydroxy-6,11-dioxotetracen-5-olate

2,4,7,9-Tetrahydroxy-6,11-dioxotetracen-5-olate

C18H9O7- (337.0348264)


   
   

Oxythiamine chloride hydrochloride

Oxythiamine chloride hydrochloride

C12H17Cl2N3O2S (337.04184820000006)


D009676 - Noxae > D000963 - Antimetabolites

   

5-amino-1-(5-phosphonato-D-ribosyl)imidazolium-4-carboxylate(2-)

5-amino-1-(5-phosphonato-D-ribosyl)imidazolium-4-carboxylate(2-)

C9H12N3O9P-2 (337.0311152)


COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

N-[2-(2,6-dichloroanilino)-2-oxoethyl]-N-methyl-4-pyridinecarboxamide

N-[2-(2,6-dichloroanilino)-2-oxoethyl]-N-methyl-4-pyridinecarboxamide

C15H13Cl2N3O2 (337.0384778)


   

N-[2-(methylthio)phenyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide

N-[2-(methylthio)phenyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide

C15H15NO4S2 (337.044247)


   

[(4S,5R)-3-(4-amino-2-oxopyrimidin-1-yl)-2-fluoro-4,5-dihydroxycyclopenten-1-yl]methyl dihydrogen phosphate

[(4S,5R)-3-(4-amino-2-oxopyrimidin-1-yl)-2-fluoro-4,5-dihydroxycyclopenten-1-yl]methyl dihydrogen phosphate

C10H13FN3O7P (337.04751300000004)


   

versicolorin A(1-)

versicolorin A(1-)

C18H9O7 (337.0348264)


A phenolate anion obtained by deprotonation of the 8-hydroxy group of versicolorin A. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).

   

5-amino-1-(5-phosphonato-D-ribosyl)imidazolium-4-carboxylate(2-)

5-amino-1-(5-phosphonato-D-ribosyl)imidazolium-4-carboxylate(2-)

C9H12N3O9P (337.0311152)


An organophosphate oxoanion that is the major structure at pH 7.3 of 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylic acid.